Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24339717 | 0.83 | KMT2A (0.47) | MEN1KMT2AHASPINKDM4ELMNA | |
| SCHEMBL24340060 | 0.81 | MEN1 (0.39) | MEN1KMT2AHASPINKDM4ELMNA | |
| SCHEMBL24339632 | 0.80 | MEN1 (0.38) | MEN1KMT2AHASPINKDM4ELMNA | |
| SCHEMBL30862164 | 0.80 | MEN1 (0.38) | MEN1KMT2AHASPINKDM4ELMNA | |
| SCHEMBL15566093 | 0.80 | HASPIN (0.41) | MEN1KMT2AHASPINALDH1A1L3MBTL1 | |
| SCHEMBL29897656 | 0.80 | HASPIN (0.41) | MEN1KMT2AHASPINALDH1A1L3MBTL1 | |
| SCHEMBL1493979 | 0.78 | KMT2A (0.44) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL24339729 | 0.76 | MEN1 (0.36) | MEN1KMT2AHASPINLMNA | |
| SCHEMBL15566652 | 0.76 | HASPIN (0.33) | HASPIN | |
| SCHEMBL26341107 | 0.76 | KMT2A (0.47) | MEN1KMT2AHASPINKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-115003671-B | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-115003671-A | JNK inhibitors, pharmaceutical compositions and uses thereof | 武汉朗来科技发展有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022048684-A1 | JNK INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2022-03-10 | — | — | WO | disclosed |
| EP-3959214-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-9725462-B2 | Pyridopyrimidine derivatives as protein kinase inhibitors | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| US-9725462-B2 | Pyridopyrimidine derivatives as protein kinase inhibitors | MERCK PATENT GMBH (DE) | 2017-08-08 | — | — | US | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-2882746-B1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2882746-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
| WO-2014023385-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | MEN1 2928/4885KMT2A 51/4885HASPIN 2871/4885 |
| US-20150218186-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | SYK, LYN, IRAK1 | MEN1 3254/4885KMT2A 1680/4885HASPIN 1212/4885 |
| US-12421228-B2 | Naphthyridine derivatives as PRC2 inhibitors | BMI1, EZH2, SUZ12 | MEN1 2928/4885KMT2A 51/4885HASPIN 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.